- Home
- ZBAI vs PALI Comparison
ZBAI vs PALI Comparison
Compare ZBAI & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- PALI
- Stock Information
- Founded
- ZBAI 2015
- PALI 1996
- Country
- ZBAI United States
- PALI United States
- Employees
- ZBAI N/A
- PALI N/A
- Industry
- ZBAI Professional Services
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZBAI Consumer Discretionary
- PALI Health Care
- Exchange
- ZBAI Nasdaq
- PALI Nasdaq
- Market Cap
- ZBAI 6.5M
- PALI 7.5M
- IPO Year
- ZBAI N/A
- PALI N/A
- Fundamental
- Price
- ZBAI $6.68
- PALI $0.58
- Analyst Decision
- ZBAI
- PALI Strong Buy
- Analyst Count
- ZBAI 0
- PALI 2
- Target Price
- ZBAI N/A
- PALI $12.00
- AVG Volume (30 Days)
- ZBAI 27.0K
- PALI 665.0K
- Earning Date
- ZBAI 06-06-2025
- PALI 08-11-2025
- Dividend Yield
- ZBAI N/A
- PALI N/A
- EPS Growth
- ZBAI N/A
- PALI N/A
- EPS
- ZBAI N/A
- PALI N/A
- Revenue
- ZBAI $720,000.00
- PALI N/A
- Revenue This Year
- ZBAI N/A
- PALI N/A
- Revenue Next Year
- ZBAI N/A
- PALI N/A
- P/E Ratio
- ZBAI N/A
- PALI N/A
- Revenue Growth
- ZBAI 44.00
- PALI N/A
- 52 Week Low
- ZBAI $4.83
- PALI $0.57
- 52 Week High
- ZBAI $45.00
- PALI $4.32
- Technical
- Relative Strength Index (RSI)
- ZBAI 55.05
- PALI 29.75
- Support Level
- ZBAI $5.65
- PALI $0.70
- Resistance Level
- ZBAI $6.43
- PALI $0.69
- Average True Range (ATR)
- ZBAI 0.60
- PALI 0.05
- MACD
- ZBAI 0.19
- PALI -0.01
- Stochastic Oscillator
- ZBAI 73.83
- PALI 2.05
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.